Lexicon Pharmaceuticals (LXRX) 13.12 $LXRX
Lexicon Pharmaceuticals (LXRX) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 7:23AM CST
As of late, it has definitely been a great time to be an investor in Lexicon Pharmaceuticals, Inc. (LXRX)
LXRX: 13.12 (+0.40)
Lexicon To Present At The Stifel 2015 Healthcare Conference And The Jefferies 2015 Global Healthcare Conference
PR Newswire - Thu Nov 12, 7:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Stifel 2015 Healthcare Conference on Tuesday, November 17, 2015 at 8:45 a.m. ET in New York and at the Jefferies 2015 Global Healthcare Conference on Thursday, November 19, 2015 at 8:00 a.m. GMT (3:00 a.m. ET) in London. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 13.12 (+0.40)
Lexicon Pharmaceuticals (LXRX) Jumps: Stock Rises 23.7%
Zacks Equity Research - Zacks Investment Research - Mon Nov 09, 7:15AM CST
Lexicon Pharmaceuticals, Inc. (LXRX) shares rose almost 24%in the last trading session.
LXRX: 13.12 (+0.40)
Lexicon Pharmaceuticals Explodes Higher -- Here's What's Fueling the Surge
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 06, 3:16PM CST
What: Shares of Lexicon Pharmaceuticals , a clinical-stage biopharmaceutical company focused on the development of small-molecule treatments to fight a host of diseases, rocketed higher by as much as 38% shortly after the start of Friday's trading...
LXRX: 13.12 (+0.40), SNY: 43.59 (+0.47)
Stock Futures Sag On Jobs Data; Qorvo, Nvidia Lead Surging Chips
at Investor's Business Daily - Fri Nov 06, 8:03AM CST
Stock futures leaned further into narrow losses Friday after a strong October job report ratcheted up rate hike pressure on the Federal Reserve. Dow futures dipped 4.4 points below fair market value. Nasdaq 100 futures whittled off 3.2 points. S&P...
ZSPH: 89.53 (+0.04), LXRX: 13.12 (+0.40), TRIP: 77.65 (-0.90), BA: 145.88 (+1.46), NVDA: 30.36 (-0.04), QRVO: 54.64 (+2.80), AZN: 33.37 (+0.59), EBIX: 37.08 (+1.78), DATA: 93.58 (+1.06), WTW: 23.82 (+0.31), AVGO: 122.48 (+1.01)
Sanofi and Lexicon Pharmaceuticals To Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes
PR Newswire - Fri Nov 06, 7:00AM CST
Sanofi and Lexicon Pharmaceuticals (NASDAQ: LXRX), Inc. announced today that they have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.
SAN: 5.34 (+0.04), LXRX: 13.12 (+0.40), SNY: 43.59 (+0.47)
Global Human Insulin Market 2015-2019 - Increasing R&D for Novel Mechanisms with Eli Lilly, Novo Nordisk & Sanofi Dominating
M2 - Fri Nov 06, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/l7t3hm/global_human) has announced the addition of the "Global Human Insulin Market 2015-2019" report to their offering. The global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019 The report includes the present scenario and the growth prospects of the global human insulin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes. The report includes a discussion of the key vendors operating in this market. The key players in the market are extending their support to academic institutions for R&D of innovative products for diabetes care. For instance, Sanofi Diabetes collaborated with academic institutions such as Helmholtz Zentrum and Charite to support R&D in the diabetes care segment. The recent collaboration of Sanofi and Gubra to discover new targets for diabetes is based on the consortium between the University of Copenhagen, Gubra and Gentofte Hospital, which is partly funded by the Danish National Advanced Technology foundation. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharma companies, which is expected to support the growth of the market. According to the report, diabetes is managed by the administration of insulin on a lifelong basis. However, insulin-based therapies are incapable of controlling blood glucose levels completely and are often associated with undesirable effects such as nocturnal hypoglycemia. During the fasting stage, glucose utilization increases and free fatty acid utilization decreases in the muscle cells, leading to hypoglycemia. In addition, fat breakdown decreases and fat storage increases in the liver cells, leading to weight gain. Severe hypoglycemic events and weight gain often result in poor patient compliance. Administered insulin therapies have lesser activity in liver and more activity in the periphery as compared to that of endogenous insulin. Therefore, there is a need to develop insulin therapies with better efficacy and safety profile, which is in turn driving market growth. Further, the report states that the global human insulin market is witnessing patent expiries for major brands. Key vendors - Eli Lilly - Novo Nordisk - Sanofi Other prominent vendors - Biocon - Biodel - Biogenomics - Boehringer Ingelheim - Bristol-Myers Squibb - Diamyd Medical - Diasome Pharmaceuticals - DiaVacs - Pfizer - Generex Biotechnology - Lexicon Pharmaceuticals - Macrogenics - Merck - Oramed Pharmaceuticals - Osiris Therapeutics - Thermalin Diabetes - Tolerion - Wockhardt - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/l7...obal_human
NVO: 53.92 (+0.66), LXRX: 13.12 (+0.40), ORMP: 6.94 (-0.06), MRK: 53.78 (+0.08), OSIR: 11.04 (-2.94), LLY: 81.26 (+0.03), BMY: 65.70 (+0.68), XOMA: 1.38 (+0.05)
Sanofi partners with Lexicon Pharmaceuticals for the development and commercialisation of sotagliflozin as a potential treatment option for diabetes
M2 - Fri Nov 06, 5:27AM CST
Healthcare company Sanofi (EURONEXT:SAN)(NYSE:SNY) revealed on Thursday that it has entered into a collaboration and license agreement for the development and commercialisation of sotagliflozin as a potential treatment option for people with diabetes, in partnership with Lexicon Pharmaceuticals (LXRX).
SAN: 5.34 (+0.04), LXRX: 13.12 (+0.40), SNY: 43.59 (+0.47)
Lexicon reports 3Q loss
Automated Insights - Fri Nov 06, 5:07AM CST
THE WOODLANDS, Texas (AP) _ Lexicon Pharmaceuticals Inc. (LXRX) on Friday reported a loss of $35.3 million in its third quarter.
LXRX: 13.12 (+0.40)
Lexicon Pharmaceuticals Reports 3rd Quarter Financial Results And Discusses Collaboration With Sanofi For Sotagliflozin
PR Newswire - Fri Nov 06, 5:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the third quarter ended September 30, 2015 and provided an overview of key milestones for the company's lead drug candidates.
LXRX: 13.12 (+0.40)
Lexicon To Report Third Quarter 2015 Financial Results On November 6, 2015
PR Newswire - Thu Nov 05, 3:01PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2015 financial results on Friday, November 6, 2015 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for the third quarter 2015 at 8:00 a.m. Eastern Time on November 6, 2015.
LXRX: 13.12 (+0.40)
Cancer Patients Treated With Lexicon's Telotristat Etiprate Report Improved Function And Well-Being
PR Newswire - Mon Oct 19, 6:00AM CDT
Lexicon Pharmaceuticals, Inc.'s (Nasdaq: LXRX) telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas.
LXRX: 13.12 (+0.40)
Lexicon Announces Telotristat Etiprate Data To Be Presented At North American Neuroendocrine Tumor Society Annual Symposium
PR Newswire - Fri Oct 09, 7:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from the TELESTAR Phase 3 clinical study of telotristat etiprate has been accepted for presentation at the North American Neuroendocrine Tumor Society annual symposium to be held from October 15-17, in Austin, Texas. In addition, data from interviews with patients who completed the randomized treatment portion of the TELESTAR study will be presented for the first time in a poster session.
LXRX: 13.12 (+0.40)
Mice Model Market (Model Type, Specialty, Services, and Geography): Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
M2 - Fri Oct 02, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7xrl2c/mice_model_market) has announced the addition of the "Mice Model Market (by Model Type, by Specialty, by Services, and by Geography): Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023" report to their offering. The global mice model market was valued at USD 1,008.1 million in 2014 and is projected to reach USD 1,749.3 million in 2023, expanding at a CAGR of 6.4% from 2015 to 2023. Major factor boosting the growth of the market is the growing application of mice models not only in the field of basic research, but also in applied field of drug development and discovery. Development of mice models of human diseases has progressed rapidly in the past few years. Mice model has become indispensable in the evaluation of established and experimental treatment strategies, especially in cancer, cardiovascular diseases, metabolic anomalies, and neurological disorders. Mice model applications in drug discovery include development of new therapeutic strategies for the treatment of human diseases, target identification and validation, drug screening and lead optimization, and toxicity and safety screening. Furthermore, advancements in genetic engineering assisting in evaluating drug mechanism of action and its responses are expected to impact the growth of the drug discovery market. On the other hand, factors such as stringent regulatory framework that require precise control on use of animals in laboratories, rising concern on animal cruelty, and ethical concerns over the use of animals could negatively impact market growth. The mice model market has been segmented into three major categories: model type, specialty, and services. Based on model type, inbred was the largest segment of the global mice model market in 2014 due to advantages such as cost effectiveness and data reproducibility. Metabolic & regulatory diseases was the largest specialty segment of the mice model market in terms of revenue in 2014. The segment accounted for 29.6% share of the market in 2014. The mice model services market is anticipated to expand at a CAGR of 7.3% from 2015 to 2023. The cryopreservation and cryorecovery services segment would expand at the highest growth rate during the forecast period as it requires less investment to maintain mice strain for a longer time. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Mice Model Market: Market Overview Chapter 4 Global Mice Model Market, by Type Chapter 5 Global Mice Model Market, by Specialty Chapter 6 Global Mice Model Market, by Services Chapter 7 Global Mice Model Market, by Geography Chapter 8 Recommendations Chapter 9 Company Profiles - Charles River Laboratories - Crescendo Biologics Limited - Deltagen Inc. - GenOway S.A. - Harlan Laboratories Inc. - ImmunoGenes AG - Lexicon Pharmaceuticals - SAGE Labs - Taconic Biosciences Inc. - Taconic Biosciences Inc. - The Jackson Laboratory - TransGenic Inc. For more information visit http://www.researchandmarkets.com/research/7x...del_market
LXRX: 13.12 (+0.40)
Lexicon Presents Positive Data from Telotristat Etiprate Study
Zacks Equity Research - Zacks Investment Research - Wed Sep 30, 4:21PM CDT
Lexicon Pharmaceuticals, Inc.'s (LXRX) has announced positive data on its prime candidate, telotristat etiprate, from a phase III study, TELESTAR.
LXRX: 13.12 (+0.40), AAVL: 7.80 (-0.04), ANIK: 41.64 (-0.19), XLRN: 35.73 (+0.15)
10 Best Nasdaq Biotech Stocks in the Third Quarter
at The Street - Wed Sep 30, 3:36PM CDT
Here are the 10 stocks in the biotech sector which had the best third-quarter.
CARA: 15.15 (-0.17), MYGN: 43.51 (+1.09), ZSPH: 89.53 (+0.04), MDCO: 41.16 (-0.35), LXRX: 13.12 (+0.40), INCY: 112.69 (+4.63), SCMP: 16.87 (-0.43), ANAC: 111.68 (+2.22), CNCE: 22.24 (-0.44), EXEL: 5.61 (+0.13)
Lexicon's Telotristat Etiprate Shows Clinical Benefit In Treating Carcinoid Syndrome In Cancer Patients When Added To Standard Of Care
PR Newswire - Tue Sep 29, 5:00AM CDT
Lexicon Pharmaceuticals, Inc.'s (Nasdaq: LXRX) telotristat etiprate was shown to have clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by long-acting somatostatin analog (SSA) therapy, the current standard of care, according to data from the Phase 3 TELESTAR study presented today at the European Cancer Congress in Vienna, Austria.
LXRX: 13.12 (+0.40)
Media Alert: Lexicon To Discuss Complete Results Of Pivotal Phase 3 TELESTAR Study
PR Newswire - Mon Sep 28, 7:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it will hold a conference call and webcast to discuss complete results of the pivotal Phase 3 TELESTAR study of oral telotristat etiprate in cancer patients with carcinoid syndrome that are not adequately controlled by the current standard of care.
LXRX: 13.12 (+0.40)
Lexicon Pharmaceuticals (LXRX) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 7:23AM CST
As of late, it has definitely been a great time to be an investor in Lexicon Pharmaceuticals, Inc. (LXRX)
LXRX: 13.12 (+0.40)
Lexicon To Present At The Stifel 2015 Healthcare Conference And The Jefferies 2015 Global Healthcare Conference
PR Newswire - Thu Nov 12, 7:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Stifel 2015 Healthcare Conference on Tuesday, November 17, 2015 at 8:45 a.m. ET in New York and at the Jefferies 2015 Global Healthcare Conference on Thursday, November 19, 2015 at 8:00 a.m. GMT (3:00 a.m. ET) in London. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 13.12 (+0.40)
Lexicon Pharmaceuticals (LXRX) Jumps: Stock Rises 23.7%
Zacks Equity Research - Zacks Investment Research - Mon Nov 09, 7:15AM CST
Lexicon Pharmaceuticals, Inc. (LXRX) shares rose almost 24%in the last trading session.
LXRX: 13.12 (+0.40)
Lexicon Pharmaceuticals Explodes Higher -- Here's What's Fueling the Surge
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 06, 3:16PM CST
What: Shares of Lexicon Pharmaceuticals , a clinical-stage biopharmaceutical company focused on the development of small-molecule treatments to fight a host of diseases, rocketed higher by as much as 38% shortly after the start of Friday's trading...
LXRX: 13.12 (+0.40), SNY: 43.59 (+0.47)
Stock Futures Sag On Jobs Data; Qorvo, Nvidia Lead Surging Chips
at Investor's Business Daily - Fri Nov 06, 8:03AM CST
Stock futures leaned further into narrow losses Friday after a strong October job report ratcheted up rate hike pressure on the Federal Reserve. Dow futures dipped 4.4 points below fair market value. Nasdaq 100 futures whittled off 3.2 points. S&P...
ZSPH: 89.53 (+0.04), LXRX: 13.12 (+0.40), TRIP: 77.65 (-0.90), BA: 145.88 (+1.46), NVDA: 30.36 (-0.04), QRVO: 54.64 (+2.80), AZN: 33.37 (+0.59), EBIX: 37.08 (+1.78), DATA: 93.58 (+1.06), WTW: 23.82 (+0.31), AVGO: 122.48 (+1.01)
Sanofi and Lexicon Pharmaceuticals To Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes
PR Newswire - Fri Nov 06, 7:00AM CST
Sanofi and Lexicon Pharmaceuticals (NASDAQ: LXRX), Inc. announced today that they have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.
SAN: 5.34 (+0.04), LXRX: 13.12 (+0.40), SNY: 43.59 (+0.47)
Global Human Insulin Market 2015-2019 - Increasing R&D for Novel Mechanisms with Eli Lilly, Novo Nordisk & Sanofi Dominating
M2 - Fri Nov 06, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/l7t3hm/global_human) has announced the addition of the "Global Human Insulin Market 2015-2019" report to their offering. The global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019 The report includes the present scenario and the growth prospects of the global human insulin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes. The report includes a discussion of the key vendors operating in this market. The key players in the market are extending their support to academic institutions for R&D of innovative products for diabetes care. For instance, Sanofi Diabetes collaborated with academic institutions such as Helmholtz Zentrum and Charite to support R&D in the diabetes care segment. The recent collaboration of Sanofi and Gubra to discover new targets for diabetes is based on the consortium between the University of Copenhagen, Gubra and Gentofte Hospital, which is partly funded by the Danish National Advanced Technology foundation. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharma companies, which is expected to support the growth of the market. According to the report, diabetes is managed by the administration of insulin on a lifelong basis. However, insulin-based therapies are incapable of controlling blood glucose levels completely and are often associated with undesirable effects such as nocturnal hypoglycemia. During the fasting stage, glucose utilization increases and free fatty acid utilization decreases in the muscle cells, leading to hypoglycemia. In addition, fat breakdown decreases and fat storage increases in the liver cells, leading to weight gain. Severe hypoglycemic events and weight gain often result in poor patient compliance. Administered insulin therapies have lesser activity in liver and more activity in the periphery as compared to that of endogenous insulin. Therefore, there is a need to develop insulin therapies with better efficacy and safety profile, which is in turn driving market growth. Further, the report states that the global human insulin market is witnessing patent expiries for major brands. Key vendors - Eli Lilly - Novo Nordisk - Sanofi Other prominent vendors - Biocon - Biodel - Biogenomics - Boehringer Ingelheim - Bristol-Myers Squibb - Diamyd Medical - Diasome Pharmaceuticals - DiaVacs - Pfizer - Generex Biotechnology - Lexicon Pharmaceuticals - Macrogenics - Merck - Oramed Pharmaceuticals - Osiris Therapeutics - Thermalin Diabetes - Tolerion - Wockhardt - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/l7...obal_human
NVO: 53.92 (+0.66), LXRX: 13.12 (+0.40), ORMP: 6.94 (-0.06), MRK: 53.78 (+0.08), OSIR: 11.04 (-2.94), LLY: 81.26 (+0.03), BMY: 65.70 (+0.68), XOMA: 1.38 (+0.05)
Sanofi partners with Lexicon Pharmaceuticals for the development and commercialisation of sotagliflozin as a potential treatment option for diabetes
M2 - Fri Nov 06, 5:27AM CST
Healthcare company Sanofi (EURONEXT:SAN)(NYSE:SNY) revealed on Thursday that it has entered into a collaboration and license agreement for the development and commercialisation of sotagliflozin as a potential treatment option for people with diabetes, in partnership with Lexicon Pharmaceuticals (LXRX).
SAN: 5.34 (+0.04), LXRX: 13.12 (+0.40), SNY: 43.59 (+0.47)
Lexicon reports 3Q loss
Automated Insights - Fri Nov 06, 5:07AM CST
THE WOODLANDS, Texas (AP) _ Lexicon Pharmaceuticals Inc. (LXRX) on Friday reported a loss of $35.3 million in its third quarter.
LXRX: 13.12 (+0.40)
Lexicon Pharmaceuticals Reports 3rd Quarter Financial Results And Discusses Collaboration With Sanofi For Sotagliflozin
PR Newswire - Fri Nov 06, 5:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the third quarter ended September 30, 2015 and provided an overview of key milestones for the company's lead drug candidates.
LXRX: 13.12 (+0.40)
Lexicon To Report Third Quarter 2015 Financial Results On November 6, 2015
PR Newswire - Thu Nov 05, 3:01PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2015 financial results on Friday, November 6, 2015 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for the third quarter 2015 at 8:00 a.m. Eastern Time on November 6, 2015.
LXRX: 13.12 (+0.40)
Cancer Patients Treated With Lexicon's Telotristat Etiprate Report Improved Function And Well-Being
PR Newswire - Mon Oct 19, 6:00AM CDT
Lexicon Pharmaceuticals, Inc.'s (Nasdaq: LXRX) telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas.
LXRX: 13.12 (+0.40)
Lexicon Announces Telotristat Etiprate Data To Be Presented At North American Neuroendocrine Tumor Society Annual Symposium
PR Newswire - Fri Oct 09, 7:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from the TELESTAR Phase 3 clinical study of telotristat etiprate has been accepted for presentation at the North American Neuroendocrine Tumor Society annual symposium to be held from October 15-17, in Austin, Texas. In addition, data from interviews with patients who completed the randomized treatment portion of the TELESTAR study will be presented for the first time in a poster session.
LXRX: 13.12 (+0.40)
Mice Model Market (Model Type, Specialty, Services, and Geography): Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
M2 - Fri Oct 02, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7xrl2c/mice_model_market) has announced the addition of the "Mice Model Market (by Model Type, by Specialty, by Services, and by Geography): Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023" report to their offering. The global mice model market was valued at USD 1,008.1 million in 2014 and is projected to reach USD 1,749.3 million in 2023, expanding at a CAGR of 6.4% from 2015 to 2023. Major factor boosting the growth of the market is the growing application of mice models not only in the field of basic research, but also in applied field of drug development and discovery. Development of mice models of human diseases has progressed rapidly in the past few years. Mice model has become indispensable in the evaluation of established and experimental treatment strategies, especially in cancer, cardiovascular diseases, metabolic anomalies, and neurological disorders. Mice model applications in drug discovery include development of new therapeutic strategies for the treatment of human diseases, target identification and validation, drug screening and lead optimization, and toxicity and safety screening. Furthermore, advancements in genetic engineering assisting in evaluating drug mechanism of action and its responses are expected to impact the growth of the drug discovery market. On the other hand, factors such as stringent regulatory framework that require precise control on use of animals in laboratories, rising concern on animal cruelty, and ethical concerns over the use of animals could negatively impact market growth. The mice model market has been segmented into three major categories: model type, specialty, and services. Based on model type, inbred was the largest segment of the global mice model market in 2014 due to advantages such as cost effectiveness and data reproducibility. Metabolic & regulatory diseases was the largest specialty segment of the mice model market in terms of revenue in 2014. The segment accounted for 29.6% share of the market in 2014. The mice model services market is anticipated to expand at a CAGR of 7.3% from 2015 to 2023. The cryopreservation and cryorecovery services segment would expand at the highest growth rate during the forecast period as it requires less investment to maintain mice strain for a longer time. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Mice Model Market: Market Overview Chapter 4 Global Mice Model Market, by Type Chapter 5 Global Mice Model Market, by Specialty Chapter 6 Global Mice Model Market, by Services Chapter 7 Global Mice Model Market, by Geography Chapter 8 Recommendations Chapter 9 Company Profiles - Charles River Laboratories - Crescendo Biologics Limited - Deltagen Inc. - GenOway S.A. - Harlan Laboratories Inc. - ImmunoGenes AG - Lexicon Pharmaceuticals - SAGE Labs - Taconic Biosciences Inc. - Taconic Biosciences Inc. - The Jackson Laboratory - TransGenic Inc. For more information visit http://www.researchandmarkets.com/research/7x...del_market
LXRX: 13.12 (+0.40)
Lexicon Presents Positive Data from Telotristat Etiprate Study
Zacks Equity Research - Zacks Investment Research - Wed Sep 30, 4:21PM CDT
Lexicon Pharmaceuticals, Inc.'s (LXRX) has announced positive data on its prime candidate, telotristat etiprate, from a phase III study, TELESTAR.
LXRX: 13.12 (+0.40), AAVL: 7.80 (-0.04), ANIK: 41.64 (-0.19), XLRN: 35.73 (+0.15)
10 Best Nasdaq Biotech Stocks in the Third Quarter
at The Street - Wed Sep 30, 3:36PM CDT
Here are the 10 stocks in the biotech sector which had the best third-quarter.
CARA: 15.15 (-0.17), MYGN: 43.51 (+1.09), ZSPH: 89.53 (+0.04), MDCO: 41.16 (-0.35), LXRX: 13.12 (+0.40), INCY: 112.69 (+4.63), SCMP: 16.87 (-0.43), ANAC: 111.68 (+2.22), CNCE: 22.24 (-0.44), EXEL: 5.61 (+0.13)
Lexicon's Telotristat Etiprate Shows Clinical Benefit In Treating Carcinoid Syndrome In Cancer Patients When Added To Standard Of Care
PR Newswire - Tue Sep 29, 5:00AM CDT
Lexicon Pharmaceuticals, Inc.'s (Nasdaq: LXRX) telotristat etiprate was shown to have clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by long-acting somatostatin analog (SSA) therapy, the current standard of care, according to data from the Phase 3 TELESTAR study presented today at the European Cancer Congress in Vienna, Austria.
LXRX: 13.12 (+0.40)
Media Alert: Lexicon To Discuss Complete Results Of Pivotal Phase 3 TELESTAR Study
PR Newswire - Mon Sep 28, 7:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it will hold a conference call and webcast to discuss complete results of the pivotal Phase 3 TELESTAR study of oral telotristat etiprate in cancer patients with carcinoid syndrome that are not adequately controlled by the current standard of care.
LXRX: 13.12 (+0.40)
